Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Crochet, Gilles; Iacoboni, Gloria; Couturier, Audrey; Bachy, Emmanuel; Iraola-Truchuelo, Josu; Gastinne, Thomas; Cartron, Guillaume; Fradon, Tom; Lesne, Bastien; Kwon, Mi; Gounot, Romain; Martínez-Cibrian, Nuria; Castilla-Llorente, Cristina; Abrisqueta, Pau; Guerreiro, Manuel; Sarkozy, clémentine; Aspa-Cilleruelo, José María; Camus, Vincent; Guidez, Stéphanie; Chauchet, Adrien; Deconinck, Eric; Bouabdallah, Krimo; Bosch, Francesc; Barba, Pere; Morschhauser, Franck; Roch, Houot

doi:10.1182/blood.2024024526

In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

This content is only available as a PDF.

2024

You do not currently have access to this content.

Sign in via your Institution

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Article PDF first page preview

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma

Article PDF first page preview

This feature is available to Subscribers Only

My Account

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only